Introduction

C-Reactive protein (CRP)
1 is a prototypical acute-phase reactant. In healthy subjects, serum concentration of CRP is Ͻ 1 g/ml. However, serum levels can increase as much as 1,000-fold within 24 h after the onset of inflammation or tissue damage (1) , suggesting that this protein may initiate and/or modulate multiple responses of the host. In general, the magnitude of the CRP response is related to the severity of inflammation or the extent of tissue injury (2) . Since extravasation and activation of neutrophil granulocytes are essential in the inflammatory response, the effects of CRP on these cells are of particular importance. CRP binds with high affinity to human neutrophils (3, 4) and inhibits neutrophil activation, including chemotaxis (5), influx into alveolar space (6, 7) , and superoxide production and degranulation in response to FMLP and platelet-activating factor (8) . Stimulation of neutrophils activates a membrane-associated serine protease which leads to cleavage of biologically active peptides from CRP (9) . CRP peptides 77-82 and 201-206 have been found to inhibit neutrophil chemotaxis to FMLP in vitro (10) and to diminish neutrophil influx and protein leakage into alveoli after FMLPinduced inflammation in mice (11) .
Neutrophil extravasation into inflamed or injured areas involves a complex interaction of leukocytes with endothelial cells via regulated expression of surface adhesion molecules (12, 13) . The initial attachment of neutrophils to endothelium is mediated by L-selectin (CD62L) (12) (13) (14) (15) . L-Selectin is constitutively expressed by neutrophils and is released from neutrophils by a proteolytic cleavage within minutes after activation with a concomitant upregulation of Mac-1 (CD11b/CD18) (16, 17) . The CD18 integrins, Mac-1 and LFA-1 (CD11a/ CD18), are largely responsible for subsequent tightening of the adhesion and transendothelial migration of neutrophils via interactions with their endothelial counterreceptors, ICAM-1 and ICAM-2 (12, 13) .
This study was undertaken to examine whether CRP and CRP peptides could affect the first step of neutrophil extravasation, the L-selectin-mediated interaction of neutrophils with endothelial cells. We found that CRP at clinically relevant concentrations and CRP peptides 174-185 and 201-206, but not peptide 77-82, strongly inhibited adhesion of neutrophils to cultured endothelial cells. This was due to the loss of L-selectin expression in neutrophils through a shedding mechanism.
Methods
Antibodies and reagents. In these studies, the monoclonal antibodies (mAbs) used included FITC-conjugated mouse anti-human L-selectin mAb DREG-56 (PharMingen, San Diego, CA), R-phycoerythrinconjugated mouse anti-human CD11b mAb Leu-15 (Becton Dickinson Immunocytometry Systems, Mountain View, CA) and PerCP-conjugated mouse anti-human CD45 mAb 2D1 (Becton Dickinson). Appropriately labeled, class-matched irrelevant mouse IgG 1 was used as a negative control for each staining. The following murine mAbs were used in neutrophil-endothelial cell adhesion assays: anti-L-selectin mAb DREG-56 (IgG 1 ; PharMingen) at 20 g/ml (18, 19) ; anti-E-selectin mAb ENA-2 (IgG 1 , purified F(ab Ј ) 2 fragments, Monosan, Uden, The Netherlands) at 10 g/ml (20) , and anti-CD18 mAb L130 (IgG 1 , Becton Dickinson) at 10 g/ml. The irrelevant mAb MOPC-21 (IgG 1 , PharMingen) at 20 g/ml was used as a negative control.
Human CRP was obtained from Calbiochem-Novabiochem Corp. (La Jolla, CA). Purity of the protein was ascertained as a single silverstained protein band of 22 kD. Peptides corresponding to amino acid sequences 77-82 (Val-Gly-Gly-Ser-Glu-Ile), 174-185 (Ile-Tyr-Leu-GlyGly-Pro-Phe-Ser-Pro-Asn-Val-Leu), and 201-206 (Lys-Pro-Gln-LeuTrp-Pro) were purchased from Sigma Chemical Co. (St. Louis, MO). Purity of the peptides, as analyzed by the manufacturer, was 99%. The peptides were stored in distilled water at Ϫ 20 Њ C. Goat antihuman CRP antiserum and LPS ( Escherichia coli O111:B4) were obtained from Sigma Chemical Co.
Compound
, which inhibits shedding of L-selectin (21) , was a gift from Dr. Takashi Kei Kishimoto (Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT), and was prepared in DMSO (final concentration: 66 mol/ml) and stored at Ϫ 20 Њ C.
Whole blood incubation. Venous blood (10 ml, anticoagulated with sodium heparin, 50 U/ml) was obtained by antecubital venipuncture from nonsmoking healthy volunteers (male and female, 32-54 yr) who had not taken any drugs for at least 10 d before the experiments. Informed consent was obtained from each volunteer, and the protocol was approved by the Clinical Research Committee. White blood cell counts were between 5,000 and 9,000 cells/ l. Whole blood aliquots were transferred to polypropylene centrifuge tubes, placed on a rotator, and incubated with CRP or one of the CRP peptides (3.1-200 g/ml) for 30 min at 37 Њ C, 95% air/5% CO 2 . Preliminary experiments showed that the maximum effects that can be observed with CRP were achieved within 30 min of preincubation. In additional experiments, aliquots of blood were preincubated for 10 min with various concentrations of KD-IX-73-4 before addition of CRP or CRP peptides.
Flow cytometry analysis. Resting and treated neutrophils in whole blood were incubated with saturating concentration of fluorescent dye-conjugated anti-human L-selectin, anti-human CD11b, or antihuman CD45 mAb for 30 min at 22 Њ C, erythrocytes were lysed, and leukocytes were fixed with 2 ml of a lysing medium (FACS ® Lysing Solution; Becton Dickinson). The samples were then centrifuged, washed, and resuspended in PBS containing 0.1% sodium azide. Negative controls were obtained by omitting monoclonal antibodies. Nonspecific binding was evaluated by using appropriately labeled mouse IgG 1 . Single-color immunofluorescence staining was analyzed by a cytofluorometer (FACScan ® ; Becton Dickinson) with Lysis II software. Data from 10,000 events per sample were acquired. Antibody binding was determined as mean fluorescence intensity after gating for neutrophils by their characteristic forward and side scatter properties. The results are presented as relative fluorescence units (RFU): RFU ϭ ( FU experimental Ϫ FU isotype ) ϫ 100/( FU control Ϫ FU isotype ), where FU experimental and FU control are the CD11b or L-selectin fluorescence intensity of treated cells and cells cultured in medium only, respectively, and FU isotype is the fluorescence intensity of class-matched irrelevant antibody. Likewise, in additional experiments, suspensions of isolated neutrophils were incubated under identical conditions with the conjugated antibodies, and fluorescence was assessed as described above.
Isolation and treatment of neutrophil granulocytes. Neutrophil granulocytes were isolated from peripheral blood by centrifugation through Ficoll-Hypaque gradients (Pharmacia Diagnostics AB, Uppsala, Sweden), sedimentation through dextran (3%, wt/vol), and hypotonic lysis of erythrocytes. The resultant cell preparation contained Ͼ 97% neutrophils. Neutrophils were suspended in a modified HBSS (in mmol/liter: NaCl, 145; K 2 PO 4 , 10; CaCl 2 , 1.4; MgCl 2 , 1.2; glucose, 10; and bovine serum albumin, 250 g/ml, pH 7.4). The experiments were carried out in 1.5 ml polypropylene tubes. Neutrophils (5 ϫ 10 6 cells/ml) were incubated in HBSS with CRP or CRP peptides (3.1-200 g/ml) for 30 min at 37 Њ C. Then the cells were pelleted, and the supernatants were collected for further analysis.
Enzymatic activity of supernatants from treated neutrophils. Lactate dehydrogenase (8), ␤ -glucuronidase (8), lysozyme (8) , and gelatinase (22) were assayed as described. Enzyme release was determined as the percentage of total enzyme units released from neutrophils treated with 0.1% Triton X-100.
Neutrophil-endothelial cell attachment assay. Normal human coronary artery endothelial cells (HCAEC) and lung microvascular endothelial cells (HMVEC-L) were obtained from Clonetics Corp. (San Diego, CA) and grown in endothelial cell growth medium containing 5% FBS and supplemented with human recombinant epidermal growth factor (10 ng/ml), hydrocortisone (1 mg/ml), gentamycin (50 mg/ml), amphotericin B (50 g/ml), and bovine brain extract (3 mg/ml). HCAEC or HMVEC-L (passages 5 and 6) were seeded into 96-well microplates and grown to confluence. Cell monolayers were carefully washed, overlaid with 250 l RPMI 1640 medium containing 10% FBS, and stimulated with LPS (1 g/ml) for 6-8 h at 37 Њ C in a 5% CO 2 atmosphere. The cells were then washed three times with 200 l RPMI 1640 medium containing 10% FBS and 2 ϫ 10 5 51
Cr-labeled neutrophils in 100 l were added. In another set of experiments, LPSactivated HCAEC were incubated for 15 min with ENA-2 or MOPC-21 mAbs before addition of neutrophils. The mAb reactive with E-selectin was also added back to the neutrophil suspensions so that mAb ENA-2 was present throughout the assay. Radiolabeled neutrophils were incubated with DREG-56, L130, or MOPC-21 mAb for 15 min at 37 Њ C before addition to the endothelial cell monolayers. After incubation of endothelial cells with neutrophils for 30 min at 4 or 37 Њ C on an orbital shaker at 90 rpm, loosely adherent or unattached neutrophils were washed three times with RPMI 1640 medium containing 10% FBS, and the endothelial monolayer plus the adherent neutrophils were lysed in 200 l of 0.1 mol/liter NaOH. The number of neutrophils in each experiment was estimated from the radioactivity of a control sample. Inhibition of neutrophil attachment was calculated using the level of attachment to unstimulated endothelial cells as the baseline, and the level of attachment of LPS-stimulated endothelial cells as the maximal value. Neither treatment of HCAEC with any of the antibody used in these studies nor carrying out the assays at 4 or 37 Њ C altered the integrity of viable endothelial monolayers.
sL-Selectin ELISA. Soluble L-selectin (sL-selectin) was quantitated in the supernatant of CRP-treated neutrophils by a specific ELISA (Bender MedSystems, Vienna, Austria). The detection limit of the assay was 0.4 ng/ml. Intraassay coefficient of variation was 4.6% at the midpoint (3.2 ng/ml) of the standard curve. There was no cross-reactivity with CRP or any of the CRP peptides studied.
Statistical analysis. Results are expressed as means Ϯ SEM. Statistical comparisons were made by ANOVA using ranks (Kruskal-Wallis test) followed by Dunn's multiple contrast hypothesis test to identify differences between various treatments, or by the Wilcoxon signed rank test and Mann-Whitney U test for paired and unpaired observations, respectively. P values Ͻ 0.05 were considered significant for all tests.
Results
CRP and peptides derived from CRP attenuate adhesion of neutrophils to LPS-stimulated endothelial cells.
To study whether CRP or CRP peptides could affect neutrophil adhesion, we analyzed the attachment of neutrophils to HMVEC-L and HCAEC under nonstatic conditions. Only a few neutrophils were able to bind to unstimulated endothelial cells. However, when endothelial cells were activated with LPS (1 g/ml), on average 3.3-and 6.8-fold more neutrophils adhered to treated than to untreated HCAEC and HMVEC-L, respectively ( Fig.  1) . Preincubation of neutrophils with CRP inhibited neutrophil adhesion to LPS-activated HCAEC and HMVEC-L in a concentration-dependent manner with apparent IC 50 values of 20 and 22 g/ml, respectively (Fig. 1) . No significant decreases in adhesion could be detected when untreated neutrophils were added to HCAEC cultured with LPS in the presence of 200 g/ml CRP (4.2 Ϯ 1.3 ϫ 10 4 cells vs. 3.9 Ϯ 1.1 ϫ 10 4 cells attached per well, n ϭ 3). Preincubation of neutrophils with peptide 174-185 or 201-206 also attenuated neutrophil adherence to HCAEC, albeit these peptides showed a weaker inhibitory effect than CRP (Fig. 1 A ) . Similar results were obtained with peptide 201-206 using HMVEC-L (Fig. 1 B ) . In contrast, peptide 77-85 did not inhibit neutrophil adhesion (Fig. 1) .
Preincubation of neutrophils with anti-CRP antiserum did not affect their adhesion to HCAEC. However, when CRP was preincubated with CRP antiserum for 20 min at 37 Њ C before addition to neutrophils, neutrophil adhesion was nearly completely restored (number of neutrophils attached to LPSactivated HCAEC: medium only, 4.2 Ϯ 1. (23), we assayed the contribution of L-selectin, E-selectin, and CD18 to the binding interaction and studied the possibility that CRP could affect E-selectin or CD18 function by using function-blocking mAbs. The binding assays were carried out at 37 Њ C as well as at 4 Њ C, where L-selectin shedding and CD18-dependent adhesion are minimal (23) .
At 37 Њ C, a significant proportion of neutrophil-HCAEC attachment was blocked by mAb binding to E-selectin (40 Ϯ 8%, n ϭ 3), L-selectin (47 Ϯ 6%), or CD18 (22 Ϯ 2%) (Fig. 2 A ) . The combination of these mAbs inhibited the binding of neutrophils by 80-86% (Fig. 2 A ) . Adhesion of neutrophils treated with CRP (200 g/ml) and anti-L-selectin mAb was similar to those observed with neutrophils treated with CRP or anti-L-selectin mAb alone (Fig. 2 B ) . Combination of CRP with either anti-E-selectin or anti-CD18 mAb resulted in inhibition of neutrophil binding similar to those observed with combinations of anti-L-selectin mAb and anti-E-selectin or anti-CD18 mAb, respectively (Fig. 2 A ) . Combining CRP, anti-E-selectin, and anti-CD18 mAbs blocked ‫ف‬ 85% of adhesion. Thus, CRP acts in concert with anti-E-selectin and anti-CD18 mAb, but not with anti-L-selectin mAb, to inhibit neutrophil attachment to LPS-activated HCAEC, and in this assay system, L-selectin, E-selectin, and CD18 in combination can account for nearly all neutrophil attachment.
At 4ЊC, neutrophil adhesion was inhibited by anti-L-selectin mAb (54Ϯ3%, n ϭ 3) and anti-E-selectin mAb (55Ϯ5%), whereas anti-CD18 mAb had little effect (9Ϯ2% inhibition) (Fig. 2 B) . Again, combining these mAb blocked ‫ف‬ 80% of adhesion. CRP in combination with anti-L-selectin mAb produced inhibition of neutrophil adhesion similar to that observed with CRP or anti-L-selectin mAb alone (Fig. 2 B) . The inhibitory actions of CRP and anti-E-selectin or anti-CD18 mAb were additive, and did not differ from those observed with a combination of anti-L-selectin and anti-E-selectin or anti-CD18 mAb, respectively (Fig. 2 B) . The combination of CRP with anti-E-selectin and anti-CD18 mAbs inhibited 78-85% of neutrophil adhesion. Assayed at either 4 or 37ЊC, qualitatively similar results were obtained when peptide 174-185 or 201-206 was combined with anti-E-selectin or anti-CD18 mAb (data not shown), and the control mAb (MOPC-21) gave results similar to medium alone (Fig. 2, A and B) .
KD (Fig. 3) . KD-IX-73-4 alone did not affect neutrophil adhesion to activated endothelial cells (Fig. 3) .
L-Selectin expression on neutrophils is downregulated by CRP and peptides derived from CRP.
We next determined whether the effect of CRP and CRP peptides on neutrophil adhesiveness resulted from diminished expression of L-selectin. Flow cytometry analysis of whole blood treated with CRP showed that the neutrophil surface expression of L-selectin was downregulated by CRP in a concentration-dependent fashion with an apparent IC 50 concentration of 24 g/ml (Fig. 4) . CRP showed a stronger effect than peptides 174-185 and 201-206, while peptide 77-82 had no effect on L-selectin expression ( Fig. 4) . Neither CRP nor any of the CRP peptides studied affected basal expression of L-selectin when the experiments were performed at 4ЊC (data not shown). Anti-CRP antiserum almost completely prevented the effect of CRP on L-selectin expression (mean fluorescence intensity for L-selectin: medium only, 84Ϯ7; CRP, 200 g/ml, 47Ϯ4; anti-CRP antiserum plus CRP, 80Ϯ6, n ϭ 6). Qualitatively and quantitatively similar effects on L-selectin expression were seen after incubation of isolated neutrophils with CRP or CRP peptides (data not shown).
KD-IX-73-4 prevents downregulation of neutrophil L-selectin expression elicited by CRP and peptides 174-185 and 201-206. Preincubation of whole blood aliquots with KD-IX-73-4
inhibited CRP-induced downregulation of L-selectin expression in a concentration-dependent fashion with an apparent IC 50 concentration of ‫ف‬ 1.6 nmol/ml (Fig. 5) . Similarly, the effects of peptides 174-185 and 201-206 were also completely inhibited by 44 nmol/ml KD-IX-73-4 (data not shown). KD-IX-73-4 did not affect the characteristic forward-and side-light scatter profiles of neutrophils challenged with CRP or CRP peptides (data not shown).
Effect of CRP and peptides derived from CRP on neutrophil activation. Since L-selectin is rapidly downregulated from the surface of neutrophils upon cell activation, we investigated the possibility that CRP or CRP-derived peptides could activate neutrophils. We analyzed neutrophil surface expression of CD11b and CD45, which is upregulated upon activation and degranulation. CRP at a concentration of 200 g/ml failed to modify baseline expression of CD11b or CD45 upon 30 min of whole blood treatment (Fig. 6) . Similar results were obtained with CRP-derived peptides studied (data not shown).
Incubation of isolated neutrophils with CRP or any of the CRP peptides for 30 min did not induce a significant release of ␤-glucuronidase (a marker for azurophil granules), lysozyme (a marker for specific plus azurophil granules), or gelatinase (a marker for tertiary granules) ( Table I) . As a positive control, neutrophils challenged with platelet-activating factor secreted high amounts of gelatinase (Table I) . Lactate dehydrogenase release never exceeded 2% of the total cell content, and was similar in the absence and presence of CRP or CRP peptides (data not shown), indicating that cellular integrity was not affected.
Shedding of L-selectin by CRP and peptides derived from CRP. To determine whether CRP and CRP peptides exert their inhibitory effect on neutrophil-endothelial cell adhesion by the cleavage and shedding of L-selectin, we measured sLselectin in the cell-free supernatants of neutrophils incubated with CRP or CRP peptides for 30 min. CRP at 200 g/ml produced more than a threefold increase in sL-selectin concentrations, which can be prevented by anti-CRP antiserum (Fig. 7) . The maximum amount of sL-selectin detected after CRP was ‫ف‬ 76% of the amount measured in the supernatant from neutrophils challenged with platelet-activating factor (Fig. 7) . Lower amounts of sL-selectin were detected in the supernatant medium of neutrophils incubated with peptides 174-185 and 201-206 at 200 g/ml concentration (Fig. 7) , corresponding to their potency to downregulate surface expression of L-selectin. In contrast, peptide 77-82 did not increase sL-selectin concentration (Fig. 7) .
Discussion
We describe in this report that a novel mechanism by which CRP and CRP-derived peptides 174-185 and 201-206 may affect the inflammatory response is the modulation of adhesion of neutrophils to the endothelium. CRP or CRP-derived peptides 174-185 and 201-206 acting on neutrophils diminish attachment of resting neutrophils to LPS-stimulated endothelial cells via downregulation and shedding of L-selectin from the surface of neutrophils.
The neutrophil-endothelial cell attachment assay was used to study the first step of neutrophil migration. To simulate blood flow, the experiments were performed under nonstatic conditions (24) . In agreement with results previously reported by other authors (23) (24) (25) , mAbs against L-selectin, E-selectin, and CD18 each partially inhibited the adhesion of neutrophils to HCAEC at 37ЊC, whereas together they inhibited 80-86% of neutrophil adhesion. These results suggest that each of these adhesion molecules function independently and interact in a cooperative fashion to promote optimal neutrophil adhesion to HCAEC. To our knowledge, this study demonstrates for the first time that CRP can effectively attenuate the neutrophil attachment to LPS-activated human endothelial cells. This inhibition can be attributed to an effect of CRP on neutrophils rather than endothelial cells, as no significant decreases in neutrophil attachment were observed after culture of endothelial cells with LPS in the presence of CRP. Indeed, this study provides three lines of evidence indicating that CRPinduced inhibition of neutrophil adhesion to endothelial cells is predominantly attributable to the shedding of L-selectin. First, the shedding of L-selectin correlated with reduced neutrophil adhesion. Second, CRP or a function-blocking anti-L-selectin mAb resulted in similar reductions in neutrophil adhesion to HCAEC. Furthermore, the inhibitory actions of CRP and anti-L-selectin mAb were not additive, as assayed at both 37 and 4ЊC, where the L-selectin-dependent component of adhesion is larger (23, and this study). On the other hand, the inhibition with CRP was additive with anti-E-selectin and anti-CD18 mAbs, and did not differ from the inhibition observed when anti-L-selectin mAb was combined with anti-E-selectin or anti-CD18 mAb. These findings would indicate that CRP neither affected E-selectin or CD18 function nor interfered with the E-selectin ligand or ICAM-1/ICAM-2 under our experimental conditions. Third, the L-selectin shedding inhibitor KD-IX-73-4 (21) at a concentration which completely inhibited CRP-induced downregulation of L-selectin expression also prevented the effects of CRP on neutrophil adhesion. The finding that CRP inhibits L-selectin-dependent adhesion may be of particular importance, because L-selectin may function as the initial attachment receptor to activated endothelium, as it occurs during both in vitro and in vivo rolling at physiologic flow rates (14, 15) . CRP inhibited neutrophil adhesion to both HCAEC and HMVEC-L with similar potency, indicating its ability to attenuate neutrophil adhesion in different parts of the vasculature. Our observations would explain, at least in part, the mechanism by which CRP prevented leukocyte accumulation in experimental alveolitis (6, 7) .
It has been suggested that the specific biologic function of CRP may reside in its subsequences, with the function expressed upon degradation of the parent protein (26) . Indeed, three tuftsin-like (Thr-Lys-Pro-Arg) regions are present in the CRP molecule, and the corresponding three synthetic peptides have been found to stimulate neutrophil chemotaxis (26) . Other peptides homologous to amino acid sequences within regions 77-82 and 201-206 have been reported to inhibit human neutrophil superoxide production and chemotaxis to several stimuli (10, 27) as well as eosinophil chemotaxis (28), whereas peptide 177-182 has been shown to augment cytokine production by alveolar monocytes/macrophages and to enhance their tumoricidal activity (29, 30) . Extending previous findings with peptide 201-206 (10, 11, 27) , this study shows that this peptide can also effectively attenuate neutrophil at- Values are expressed as percentage of total cellular enzyme activity released by neutrophils to the culture medium after incubation with CRP (200 g/ml), CRP-derived peptides (200 g/ml), or platelet-activating factor (PAF, 1 mol/l) for 30 min at 37°C. Total cell enzyme activity was measured in unstimulated neutrophils disrupted by treatment with 0.1% Triton X-100. Values are meansϮSEM of four independent experiments. *P Ͻ 0.05 compared to control. tachment to both HCAEC and HMVEC-L. We were surprised that peptide 77-82, which was shown to inhibit neutrophil influx into alveoli after FMLP-induced inflammation in mice (11) , even at a concentration as high as 200 g/ml, failed to affect neutrophil adhesion to endothelial cells. However, it should be noted that significant inhibition of neutrophil chemotaxis was only observed with peptide 77-82 concentrations higher than 200 g/ml (11). Apart from differences in the assays used, the reason for this discrepancy is not readily apparent. Interestingly, peptide 177-182, which activates monocytes/ macrophages (29, 30) , showed an inhibitory potency similar to that of peptide 201-206 in attenuating adhesion of neutrophils to HCAEC. These observations suggest cell-specific effects of CRP peptides on various inflammatory cells. Our results indicated that larger concentrations of peptides 174-185 and 201-206 than native CRP were required to obtain a similar degree of inhibition. Even accounting for the fivefold molar difference between monomeric synthetic peptides and the pentameric native CRP, on a molar concentration basis, 100-150-fold more peptide than native CRP was needed to achieve a similar degree of inhibition of neutrophil attachment. It is likely that higher concentrations of CRP peptides may be needed to occupy the CRP receptor. Although we cannot rule out that CRP degradation occurred in these experimental conditions, the differences in the concentrations of native CRP and CRP peptides required to inhibit neutrophil attachment would not lend support to the hypothesis that the biologic functions of CRP may entirely reside in its degradation products (26) .
Activation of neutrophils uniformly results in downregulation of L-selectin expression as well as in upregulation of both CD11b/CD18 and CD45 expression (15, 31, 32) . Within minutes of activation, leukocytes release L-selectin from their surface by a proteolytic cleavage just outside of the transmembrane domain (15, 33, 34) . However, neither native CRP nor CRP peptides at the concentrations studied affected basal expression of CD11b/CD18 and CD45, indicating that neutrophils were not activated. This notion is further supported by the failure of CRP and CRP peptides to induce release of granule enzymes. L-Selectin shedding not only occurs in response to cell activation, but also after treatment with a chemical cross-linker (35) or certain nonsteroidal antiinflammatory drugs (25) . Although the biochemical and molecular nature of the proteolytic enzyme remains to be identified, it appears to be a constitutively active enzyme (36, 37) . Formation of an appropriate three-dimensional structure of L-selectin near the membrane has been implicated in the regulation of this proteolytic process (36, 37) . It is tempting to speculate that CRP and peptides 174-185 and 201-206 could activate this process. However, the enzyme(s) and signaling mechanisms that regulate the conformation of L-selectin in response to CRP or CRP peptides remain key areas of inquiry. Inactivation of the proteolytic enzyme by KD-IX-73-4 would block both activationdependent (21) and independent L-selectin shedding (this study). Our results indicate that downregulation of L-selectin expression is also due to the shedding of the molecule from the neutrophil surface, as quantitated by the soluble form of L-selectin in the cell-free supernatants of neutrophils cultured with CRP or CRP peptides. Although an inherent proteolytic activity of CRP itself on L-selectin cannot be completely ruled out, the observations that this phenomenon does not occur at 4ЊC coupled with the demonstration of L-selectin shedding by CRP peptides 174-185 and 201-206 would argue against this possibility.
The concentrations of CRP required in our in vitro experiments for the L-selectin shedding are below the peak plasma levels detected during the acute-phase response, suggesting that this event may also occur in vivo. However, it is difficult to establish a strict correlation between our in vitro observations and the in vivo behavior of CRP, which also depends on factors other than plasma concentrations, such as deposition at sites of tissue injury (38) and plasma metabolism (39) . To our knowledge, no information is available on the local tissue or plasma levels of CRP peptides.
These experiments permit us to suggest a novel mechanism of action for CRP. This acute-phase protein may prevent migration of neutrophils into inflammatory sites by downregulating the neutrophil surface expression of L-selectin. This hypothesis rests on two separate lines of evidence: functional, at clinically relevant plasma concentrations native CRP inhibits L-selectin-dependent adhesion of neutrophils to LPS-activated endothelial cells; and phenotypic, at similar concentrations it selectively downregulates neutrophil expression of L-selectin expression without inducing cell activation. At the site of tissue injury or inflammation, CRP may undergo conformational changes, resulting in altered forms of CRP which may promote inflammation (40) . On the other hand, considerable neutrophil-mediated degradation of CRP occurs at the same sites, resulting in peptides which either up-or downregulate leukocyte activity. Among these products, peptides 174-185 and 201-206 might also inhibit neutrophil migration, thereby contributing to demarcation of the inflammatory locus. These findings suggest that by diminishing leukocyte traffic into infected or injured tissues, native CRP and CRP peptides 174-185 and 201-206 may be a major mechanism to attenuate or limit the inflammatory response.
